Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of H7N9 Influenza Vaccine
NCT03755427Phase 2Completed
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Nov 2018
- Primary completion
- Jan 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Inactivated H7N9 Influenza Vaccine in avian influenza A H7N9 virus infection (H7N9) (2 arms), sponsored by Shanghai Institute of Biological Products. Primary endpoint: Adverse Events at 30 days. Started Nov 2018; status: completed.
02
Drugs
Inactivated H7N9 Influenza Vaccine
03
Conditions
avian influenza A H7N9 virus infection (H7N9)
Beyond the preview
Go deeper on NCT03755427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03755427.